Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get two FREE E-Books

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Depression: 21st Century Solutions + The Dark Side of Wheat


Why You Don't See Ads on GreenMedInfo

Did you know that GreenMedInfo.com is 100% member supported? It is through your membership that we are able to add research content daily, provide thoughtful articles on groundbreaking health & wellness topics, and continue to educate and empower people on the science supporting natural healing.

Our website has always offered open access to our carefully curated research (and always will) but we recently made the decision to become completely advertisement free.

In order for us to continue, we need your support more than ever. Our memberships start at only $8.00 per month and provide you with enhanced content & features.

We appreciate you supporting our mission and sharing our passion!

For more information on becoming a member of GreenMedInfo.com, click here.

Abstract Title:

Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. A first-line multicenter phase II trial of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT).

Abstract Source:

Anticancer Res. 2008 Sep-Oct;28(5B):2901-5. PMID: 19031932

Abstract Author(s):

E Wöll, T Kühr, W Eisterer, K Gattringer, R Greil, A Zabernigg, W Hilbe, J Thaler

Article Affiliation:

Saint Vincent Hospital Zams, Zams A-6511, Austria. e.woell@krankenhaus-zams.at

Abstract:

BACKGROUND: The aim of the study was to evaluate the feasibility and efficacy of an outpatient oxaliplatin/irinotecan chemotherapy in chemonaive patients suffering from unresectable gastric cancer.

MATERIALS AND METHODS: Biweekly oxaliplatin (85 mg/m2) and irinotecan (125 mg/m2) was chosen since it has been shown previously in colorectal cancer that oxaliplatin (85 mg/m2) is superior to a lower dose and toxicity of irinotecan is much lower if given fractionated. The irinotecan dose below the maximum tolerated dose takes into consideration concerns about increased toxicity in gastric cancer patients.

RESULTS: Forty-three patients with histologically proven gastric adenocarcinoma and no previous palliative chemotherapy were selected. WHO grade 3 and 4 toxicities included neutropenia in 2/43 patients, anemia in 3/43 patients, nausea in 2/43 patients and diarrhea in 4/43 patients. Response rates were assessable in 38 patients as follows: complete response in three patients (8%), partial response in 19 (50%), stable disease in 11 (29%), and progressive disease in 5 patients (13%). The median time-to-progression was 53 months and median overall survival was 9.5 months.

CONCLUSION: The outpatient combination of biweekly oxaliplatin/irinotecan was well tolerated and showed a response rate within the range of other first-line combination therapies. The favorable toxicity profile, however, renders oxaliplatin/irinotecan as an alternative first-line regimen.

Study Type : Human Study

Print Options


Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get two FREE E-Books

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Depression: 21st Century Solutions + The Dark Side of Wheat

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2018 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.